What's happening
This bill updates laws relating to generic drug products, requiring the state to maintain and publish a list of approved generics and their data.
Why it matters
Increases transparency and public access to drug information. The bill requires manufacturers to provide the state with detailed data about each generic drug, including bioequivalence studies, therapeutic equivalence, adverse events, and analytical methods. All this information must be published on a public website, making it easier for healthcare providers, patients, and researchers to evaluate generics.
Strengthens oversight and quality assurance. By mandating that only generics approved as pharmaceutically and therapeutically equivalent (or as interchangeable biological products) by the FDA are included, and explicitly excluding drugs with actual or potential bioequivalence problems, the bill aims to ensure that only high-quality generics are substituted and used.
Clarifies and modernizes legal references for pharmacists and prescribers. The bill updates references in prescription and substitution laws from an outdated section to the new law, ensuring legal clarity and consistent procedures for generic substitution in pharmacies, which may reduce confusion and enhance compliance.
Potential to improve trust in generic drugs. By making the approval process and supporting data more visible and accessible, the law could increase confidence among prescribers, pharmacists, and the public in the safety and effectiveness of generic medications.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Who cares
New York State Department of Health
The commissioner would have to publish a generic drug list meeting specified FDA approval and equivalence standards, and the department would have to post manufacturers’ supporting data freely on its website.
Generic drug manufacturers
They would have to provide the department with studies, summaries and testing methods submitted to the FDA, including equivalence and adverse-event data.
Pharmacists and prescribers
The bill would tie generic substitution rules and prescribers’ existing liability protection for authorizing substitution to the newly established list.
Patients using generic drugs or interchangeable biological products
They would gain free online access to manufacturers’ supporting data, while the state list would exclude products the FDA identifies as having actual or potential bioequivalence problems.
Headline styles
Publish Generic Drug List
Plain English, a few words. Used as the page title.
Sponsors
3 Co-sponsors
History
- Referred to ways and means
- Reported referred to ways and means
- Referred to health
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Publish Generic Drug List
In Senate Committee · Health · Sponsor Andrew J. Lanza
Full text
3 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
144
2023-2024 Regular Sessions
IN ASSEMBLY (Prefiled)
January 4, 2023
Introduced by M. of A. PAULIN, DINOWITZ, RIVERA, WEPRIN -- read once and referred to the Committee on Health
AN ACT to amend the public health law and the education law, in relation to generic drug products; and to repeal paragraph (o) of subdivision 1 of section 206 of the public health law relating thereto
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Paragraph (o) of subdivision 1 of section 206 of the public health law is REPEALED.
§ 2. The public health law is amended by adding a new section 280-d to read as follows:
§ 280-d. Generic drug products. 1. The commissioner shall establish and publish a list of drug products, referred to in this section as "generic drug" products, each of which shall meet the following conditions:
(a) The drug product has been certified or approved by the commissioner of the Federal Food and Drug Administration as being safe and effective for its labeled indications for use, and a new-drug application or an abbreviated new-drug application approved pursuant to the Federal Food, Drug, and Cosmetic Act is held for such drug product; and
(b) The commissioner of the Federal Food and Drug Administration has evaluated such drug product as: (i) pharmaceutically and therapeutically equivalent and has listed such drug product on the list of approved drug products with the therapeutic equivalence evaluations, provided, however, that the list prepared by the commissioner shall not include any drug product which the commissioner of the Federal Food and Drug Administration has identified as having an actual or potential bioequivalence problem or (ii) as an interchangeable biological product and has listed such product on the list of approved drug products with interchangeability.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD02150-01-3
2. The manufacturer of a generic drug product shall make available to the department the studies and summaries, including bioequivalence data, therapeutic equivalence data, and incidence of adverse events, and associated analytical methods, including dissolution data and test methods provided to the Federal Food and Drug Administration as part of the application for such generic drug product. The department shall make such information freely and publicly available on its website.
§ 3. Paragraphs (a) and (e) of subdivision 6 of section 6810 of the education law, paragraph (a) as amended by chapter 590 of the laws of 2011 and paragraph (e) as amended by chapter 357 of the laws of 2017, are amended to read as follows:
(a) Every prescription written in this state by a person authorized to issue such prescription shall be on prescription forms containing one line for the prescriber's signature. The prescriber's signature shall validate the prescription. Every electronic prescription shall provide for the prescriber's electronic signature, which shall validate the electronic prescription. Imprinted conspicuously on every prescription written in this state in eight point upper case type immediately below the signature line shall be the words: "THIS PRESCRIPTION WILL BE FILLED GENERICALLY UNLESS PRESCRIBER WRITES 'd a w' IN THE BOX BELOW". Unless the prescriber writes d a w in such box in the prescriber's own handwriting or, in the case of electronic prescriptions, inserts an electronic direction to dispense the drug as written, the prescriber's signature or electronic signature shall designate approval of substitution by a pharmacist of a generic drug product pursuant to [paragraph (o) of subdivision one of] section [two hundred six] two hundred eighty-d of the public health law. No other letters or marks in such box shall prohibit substitution. No prescription forms used or intended to be used by a person authorized to issue a prescription shall have 'd a w' preprinted in such box. Such box shall be placed directly under the signature line and shall be three-quarters inch in length and one-half inch in height, or in comparable form for an electronic prescription as may be specified by regulation of the commissioner. Immediately below such box shall be imprinted in six point type the words "Dispense As Written". Notwithstanding any other provision of law, no state official, agency, board or other entity shall promulgate any regulation or guideline modifying those elements of the prescription form's contents specified in this subdivision. To the extent otherwise permitted by law, a prescriber may modify only those elements of the prescription form's contents not specified in this subdivision. Notwithstanding any other provision of this section or any other law, when a generic drug is not available and the brand name drug originally prescribed is available and the pharmacist agrees to dispense the brand name product for a price that will not exceed the price that would have been charged for the generic substitute had it been available, substitution of a generic drug product will not be required. If the generic drug product is not available and a medical emergency situation, which for purposes of this section is defined as any condition requiring alleviation of severe pain or which threatens to cause disability or take life if not promptly treated, exists, then the pharmacist may dispense the brand name product at his regular price. In such instances the pharmacist must record the date, hour and nature of the medical emergency on the back of the prescription and keep a copy of all such prescriptions.
(e) No prescriber shall be subjected to civil liability arising solely from authorizing, in accordance with this subdivision, the substitution by a pharmacist of a generic drug product pursuant to [paragraph (o) of subdivision one of] section two hundred [six] eighty-d of the public health law.
§ 4. Paragraph (b) of subdivision 1 of section 6816-a of the education law, as added by chapter 776 of the laws of 1977, is amended to read as follows:
(b) The substituted drug product is contained in the list of generic drug products established pursuant to [paragraph (o) of subdivision one of] section [two hundred six] two hundred eighty-d of the public health law; and
§ 5. This act shall take effect on the ninetieth day after it shall have become a law. Effective immediately, the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized to be made and completed on or before such effective date.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.